| Proteasome inhibition measurements: clinical application ES Lightcap, TA McCormack, CS Pien, V Chau, J Adams, PJ Elliott Clinical chemistry 46 (5), 673-683, 2000 | 367 | 2000 |
| A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination VN Podust, JE Brownell, TB Gladysheva, RS Luo, C Wang, MB Coggins, ... Proceedings of the National Academy of Sciences 97 (9), 4579-4584, 2000 | 300 | 2000 |
| Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341 JA Fleming, ES Lightcap, S Sadis, V Thoroddsen, CE Bulawa, ... Proceedings of the National Academy of Sciences 99 (3), 1461-1466, 2002 | 234 | 2002 |
| Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor X He, J Riceberg, T Soucy, E Koenig, J Minissale, M Gallery, H Bernard, ... Nature chemical biology 13 (11), 1164-1171, 2017 | 205 | 2017 |
| MYC regulation of a “poor-prognosis” metastatic cancer cell state A Wolfer, BS Wittner, D Irimia, RJ Flavin, M Lupien, RN Gunawardane, ... Proceedings of the National Academy of Sciences 107 (8), 3698-3703, 2010 | 205 | 2010 |
| Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis T Schmelzle, AA Mailleux, M Overholtzer, JS Carroll, NL Solimini, ... Proceedings of the National Academy of Sciences 104 (10), 3787-3792, 2007 | 178 | 2007 |
| Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib S Chen, JL Blank, T Peters, XJ Liu, DM Rappoli, MD Pickard, S Menon, ... Cancer research 70 (11), 4318-4326, 2010 | 114 | 2010 |
| Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924 JL Blank, XJ Liu, K Cosmopoulos, DC Bouck, K Garcia, H Bernard, ... Cancer research 73 (1), 225-234, 2013 | 105 | 2013 |
| Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2 DT Worster, T Schmelzle, NL Solimini, ES Lightcap, B Millard, GB Mills, ... Science signaling 5 (214), ra19-ra19, 2012 | 92 | 2012 |
| Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924 H Liao, XJ Liu, JL Blank, DC Bouck, H Bernard, K Garcia, ES Lightcap Molecular & Cellular Proteomics 10 (11), 2011 | 80 | 2011 |
| Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways K Garcia, JL Blank, DC Bouck, XJ Liu, DS Sappal, G Hather, ... Molecular cancer therapeutics 13 (6), 1625-1635, 2014 | 61 | 2014 |
| A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models ES Lightcap, P Yu, S Grossman, K Song, M Khattar, K Xega, X He, ... Science translational medicine 13 (611), eaba7791, 2021 | 57 | 2021 |
| Method for monitoring proteasome inhibitor drug action GR Vaddi, RL Stein, LR Dick, VJ Palombella, ES Lightcap, PJ Elliott, ... US Patent 6,613,541, 2003 | 56 | 2003 |
| Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD H Liu, S Dasgupta, Y Fu, B Bailey, C Roy, E Lightcap, B Faustin BMC immunology 20, 1-18, 2019 | 53 | 2019 |
| Edge‐count probabilities for the identification of local protein communities and their organization V Farutin, K Robison, E Lightcap, V Dancik, A Ruttenberg, S Letovsky, ... Proteins: Structure, Function, and Bioinformatics 62 (3), 800-818, 2006 | 49 | 2006 |
| Slow-Binding Inhibition of γ-Aminobutyric Acid Aminotransferase by Hydrazine Analogues, ES Lightcap, RB Silverman Journal of medicinal chemistry 39 (3), 686-694, 1996 | 33 | 1996 |
| Assays for proteasome inhibition PJ Elliott, TA Soucy, CS Pien, J Adams, ES Lightcap Novel Anticancer Drug Protocols, 163-172, 2003 | 24 | 2003 |
| Discrete monomeric metaphosphate anion as an intermediate in the hydrolysis of. mu.-monothiopyrophosphate ES Lightcap, PA Frey Journal of the American Chemical Society 114 (25), 9750-9755, 1992 | 23 | 1992 |
| Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies. CN Papandreou, L Pagliaro, R Millikan, D Daliani, J Herrmann, Y Hong, ... CLINICAL CANCER RESEARCH 5, 3730S-3730S, 1999 | 16 | 1999 |
| Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359 … J Hunter, K Macbeth, FY Tsai, A Lesoon, E Lightcap, M Williamson, ... US Patent App. 10/354,358, 2003 | 12 | 2003 |
